<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00020202</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068031</org_study_id>
    <secondary_id>NCI-00-C-0123</secondary_id>
    <secondary_id>NCI-1053</secondary_id>
    <nct_id>NCT00020202</nct_id>
    <nct_alias>NCT00005656</nct_alias>
  </id_info>
  <brief_title>FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer</brief_title>
  <official_title>Phase II Study of FR901228 in Patients With Refractory or Progressive Small Cell or Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of FR901228 in treating patients who have&#xD;
      refractory or progressive small cell lung cancer or non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the response of patients with refractory or progressive small cell&#xD;
      or non-small cell lung cancer to FR901228.&#xD;
&#xD;
      II. Determine the ability of FR901228 to mediate apoptosis and target gene induction relative&#xD;
      to tumor histology in these patients.&#xD;
&#xD;
      III. Determine the toxicity of this treatment in these patients.&#xD;
&#xD;
      PROTOCOL OUTLINE: Patients are stratified according to disease histology (small cell lung&#xD;
      cancer vs non-small cell lung cancer).&#xD;
&#xD;
      Patients receive FR901228 IV over 4 hours on days 1 and 7. Treatment repeats every 21 days in&#xD;
      the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL:&#xD;
&#xD;
      A total of 18-43 patients (9-21 per arm) will be accrued for this study within 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Extensive Stage Small Cell Lung Cancer</condition>
  <condition>Stage IIIA Non-small Cell Lung Cancer</condition>
  <condition>Stage IV Non-small Cell Lung Cancer</condition>
  <condition>Recurrent Small Cell Lung Cancer</condition>
  <condition>Stage IIIB Non-small Cell Lung Cancer</condition>
  <condition>Recurrent Non-small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FR901228</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics-- Histologically or cytologically confirmed primary extensive&#xD;
        stage small cell or unresectable non-small cell lung cancer Must have received or refused&#xD;
        prior platinum-based chemotherapy and exhibited refractory or progressive disease Tumor&#xD;
        must be accessible to biopsy by bronchoscopic or percutaneous fine needle aspiration&#xD;
        technique Measurable disease outside of irradiated field or documented progression since&#xD;
        irradiation Extrathoracic metastases allowed No active intracranial or leptomeningeal&#xD;
        metastases Prior surgical resection or radiotherapy for intracranial metastatic disease&#xD;
        allowed if: No evidence of active disease on 2 MRI scans AND No requirement for&#xD;
        anticonvulsant medications or steroids to control residual symptoms --Prior/Concurrent&#xD;
        Therapy-- Biologic therapy: At least 30 days since prior biologic therapy and recovered&#xD;
        Chemotherapy: See Disease Characteristics At least 4 weeks since prior chemotherapy,&#xD;
        including nitrosoureas or mitomycin, and recovered No prior FR901228 No prior doxorubicin&#xD;
        of total dose greater than 450 mg/m2 Endocrine therapy: Not specified Radiotherapy: See&#xD;
        Disease Characteristics At least 30 days since prior radiotherapy and recovered At least 4&#xD;
        weeks since prior radiotherapy to the lung or mediastinum Surgery: See Disease&#xD;
        Characteristics --Patient Characteristics-- Age: 18 and over Performance status: ECOG 0-2&#xD;
        Life expectancy: At least 3 months Hematopoietic: Platelet count at least 100,000/mm3&#xD;
        Absolute neutrophil count at least 1,500/mm3 Hepatic: PT/PTT normal Bilirubin no greater&#xD;
        than 1.5 mg/dL Renal: Creatinine less than 1.5 mg/dL OR Creatinine clearance at least 60&#xD;
        mL/min Cardiovascular: Ejection fraction greater than 40% No unstable angina, congestive&#xD;
        heart failure, or uncontrolled cardiac dysrhythmia No deep vein thrombosis requiring&#xD;
        anticoagulation Pulmonary: No pulmonary embolism within past 6 months FEV1 and DLCO greater&#xD;
        than 30% predicted pCO2 less than 50 mm Hg on room air pO2 greater than 60 mm Hg on room&#xD;
        air Other: HIV negative No active infections Not pregnant or nursing Negative pregnancy&#xD;
        test Fertile patients must use effective contraception during and for 6 months after study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>David S. Schrump</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Surgery Branch</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2006</verification_date>
  <study_first_submitted>March 2, 2007</study_first_submitted>
  <study_first_submitted_qc>March 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2007</study_first_posted>
  <last_update_submitted>August 14, 2013</last_update_submitted>
  <last_update_submitted_qc>August 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2013</last_update_posted>
  <keyword>adult solid tumor</keyword>
  <keyword>body system/site cancer</keyword>
  <keyword>cancer</keyword>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>genetic condition</keyword>
  <keyword>lung cancer</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <keyword>small cell lung cancer</keyword>
  <keyword>solid tumor</keyword>
  <keyword>stage III non-small cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>stage, non-small cell lung cancer</keyword>
  <keyword>stage, small cell lung cancer</keyword>
  <keyword>thorax/respiratory cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Romidepsin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

